**Everest Medicines Limited**
**雲頂新耀有限公司**
*(incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 1952)**

# VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT WITH TRAVERE

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on 2 June 2026, Everest Medicines (Singapore) Pte. Ltd., a wholly-owned subsidiary of the Company (the "**Licensor**"), entered into an exclusive license and collaboration agreement (the "**Agreement**") with Travere Therapeutics, Inc. ("**Travere**"), a company listed on the Nasdaq Global Market trading under the symbol "TVTX", pursuant to which the Licensor will provide an exclusive, worldwide (except Greater China and certain countries in East and Southeast Asia) license to Travere to develop and commercialize civorebrutinib (also known as EVER001). Pursuant to the Agreement and subject to the terms and conditions thereof, the Licensor will receive an upfront payment of US$112.5 million and is eligible to receive up to US$1.03 billion in development, regulatory, and commercial milestone payments across up to five indications, as well as tiered royalties at percentages ranging from the high single-digit to double-digit based on future annual net sales thresholds. The closing will be upon satisfaction of certain conditions precedent and regulatory procedures, and the final milestone payment amounts achieved by the Licensor remain uncertain.

As innovation in rare kidney diseases continues to accelerate, patients still face significant unmet need and limited treatment options across many serious conditions. Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. Civorebrutinib is planned to be investigated in primary membranous nephropathy (PMN), immune-mediated focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), with the potential for additional indications. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. This licensing transaction will accelerate the global development and commercialization process of

civorebrutinib, provide innovative treatment options for patients worldwide. Based on the above, the Board believes that the entering into of the Agreement is in the best interests of the Company and its shareholders as a whole.

**Listing Rules Implications**

As the transaction contemplated under the Agreement is of a revenue nature in the ordinary and usual course of business of the Company, pursuant to Rule 14.04(1)(g) of the Listing Rules, the transaction contemplated thereunder does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

**About Travere**

Travere is a biopharmaceutical company with its mission ''In Rare For Life'', and that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, Travere knows the need for treatment options is urgent — that is why Travere's global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope — today and tomorrow. For more information, visit travere.com.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, Travere and its ultimate beneficial owners are third parties independent of the Company and its connected persons.

**About civorebrutinib (EVER001)**

Civorebrutinib (also known as EVER001) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell autoimmune diseases.

**We cannot guarantee that civorebrutinib will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.**

By order of the Board
**Everest Medicines Limited**
**Yifang Wu**
*Chairman and Executive Director*

Hong Kong, 2 June 2026

*As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*